CT45A1 and ovarian carcinoma: In terms of cancer, a research team first used immunopeptidomics technology to discover that CT45 was a naturally occurring cancer antigen and presented as an HLA I receptor on ovarian cancer cells, and HLA I peptides derived from CT45 promoted the ability of CTLs to kill tumor cells in patients.